All In Biotech

Drug Trial Radar · NCT00410384

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)

Last checked: Nov 20, 2026Latest source record: Feb 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 819 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

819

Actual

Start

Dec 2006

Primary completion

Sep 2009

Study completion Mar 2010

Sponsor

Lead sponsor
Human Genome Sciences Inc.Industry
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Dec 12, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • PlaceboDrug

    Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.

  • Belimumab 1 mg/kgDrug

    Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.

  • Belimumab 10 mg/kgDrug

    Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SLE Responder Index (SRI) Response Rate at Week 52Time frame: Baseline, 52 Weeks

Locations

146 sites in 19 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Arizona Arthritis and Rheumatology Research, PPLC

    Paradise Valley, Arizona

  • The University of Arizona Arthritis Center

    Tucson, Arizona

  • Talbert Medical Group

    Huntington Beach, California

  • Valerius Medical Group & Research Ctr of Greater Long Beach, Inc.

    Long Beach, California

  • University of Southern California

    Los Angeles, California

  • Wallace Rheumatic Study Center

    Los Angeles, California

  • UCLA Rheumatology

    Los Angeles, California

  • Arthritis Care Center, Inc.

    San Jose, California

  • Inland Rheumatic Disease Specialties

    Upland, California

  • Arthritis Associates of Colorado Springs

    Colorado Springs, Colorado

  • Washington Hospital Center

    Washington D.C., District of Columbia

  • Arthritis and Rheumatic Disease Specialties

    Aventura, Florida

  • University of Miami-Division of Rheumatology and Immunology

    Miami, Florida

  • Rheumatology Associates of Central Florida

    Orlando, Florida

  • Southwest Florida Clinical Research Center

    Tampa, Florida

  • Tampa Medical Group, P.A.

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Selah Medical Clinical Research Unit

    Boise, Idaho

  • Rheumatology Associates, SC

    Chicago, Illinois

  • University of Chicago Hospitals

    Chicago, Illinois

  • Medical Specialists Clinical Research

    Munster, Indiana

  • Kansas University Medical Center

    Kansas City, Kansas

  • Kentuckiana Center for Better Bone and Joint Health

    Louisville, Kentucky

  • Ochsner Clinic Foundation

    Baton Rouge, Louisiana

  • Johns Hopkins University

    Baltimore, Maryland

  • Osteoporosis and Clinical Trials Center

    Cumberland, Maryland

  • Osteoporosis & Clinical Trials Center

    Hagerstown, Maryland

  • Tufts - New England Medical Center

    Boston, Massachusetts

  • University of Michigan Medical Center - Regents of University of Michigan

    Ann Arbor, Michigan

  • Fiechtner Research, Inc.

    Lansing, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Stafford Medical Associates, PA

    Dover, New Hampshire

  • SUNY-Downstate Medical Center

    Brooklyn, New York

  • North Shore-LIJ Health System/Rheumatology and Allergy Clinic

    Lake Success, New York

  • Feinstein Institute

    Manhasset, New York

  • Hopital for Joint Diseases

    New York, New York

  • Hospital for Special Surgery

    New York, New York

  • AAIR Research Center

    Rochester, New York

  • Rheumatology Associates

    Smithtown, New York

Showing 40 of 146 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.